ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "What factors influence BTKi + BCL-2i treatment selection for patients with CLL? "
Episode Synopsis
The Lymphoma Hub was pleased to speak to Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES. We asked, what factors influence Bruton’s tyrosine kinase inhibitor (BTKi) + B-cell lymphoma 2 inhibitor (BCL-2i) treatment selection for patients with chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Johnson & Johnson. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.
In God we trust